A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial

Mike Dennis, Alan Burnett, Robert Hills, Ian Thomas, Cono Ariti, Marianne T Severinsen, Claire Hemmaway, Paul Greaves, Richard E Clark, Mhairi Copland, Nigel Russell, National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working Group

Research output: Contribution to journalJournal articleResearchpeer-review

Original languageEnglish
JournalBritish Journal of Haematology
ISSN0007-1048
DOIs
Publication statusE-pub ahead of print - 7 May 2021

Bibliographical note

© 2021 British Society for Haematology and John Wiley & Sons Ltd.

Keywords

  • AML
  • acute leukaemia
  • chemotherapy
  • elderly

Fingerprint

Dive into the research topics of 'A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat <i>versus</i> low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial'. Together they form a unique fingerprint.

Cite this